# RATIONALE-304 (NCT03663205)

> A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer

No report yet. It can be ordered.

- Drugs tested: tislelizumab
- Indication: first-line advanced non-squamous non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03663205
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: BeiGene
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Tislelizumab; Cisplatin; Carboplatin; Pemetrexed
- Enrollment: 334
- Primary outcome: Progression Free Survival (PFS) Assessed by Independent Review Committee (IRC) Assessment

## Indexed commentary on RATIONALE-304 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 6 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=rationale-304-nct03663205
